Celgene has reached a deal to buy fellow biopharmaceutical company Receptos Inc. for about $7.2 billion, enhancing its portfolio of immune-inflammatory disease treatments with the addition of Ozanimod.
from WSJ.com: US Business http://ift.tt/1O4FrJV
via IFTTT
No comments:
Post a Comment